Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Breast Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 144 articles:
HTML format

Single Articles

    November 2023
  1. CONTE B, Shermoen C, Lubarsky M, Fiser CK, et al
    Post-Mastectomy Implant Complications in the Hispanic Breast Cancer Patient Population.
    Anticancer Res. 2023;43:4953-4959.
    PubMed     Abstract available

  2. RACZ B, Kristof E, Kincses A, Dominguez-Alvarez E, et al
    Antitumor Activity of Symmetrical Selenoesters in Doxorubicin Resistant Breast Cancer.
    Anticancer Res. 2023;43:4865-4872.
    PubMed     Abstract available

  3. MIZUMOTO S, Inubushi S, Miki M, Nakamura H, et al
    Target-Oriented Classification of Triple-negative Breast Cancer.
    Anticancer Res. 2023;43:5067-5072.
    PubMed     Abstract available

  4. USHIYAMA Y, Horimoto Y, Murakami F, Ishizuka Y, et al
    Relationship Between Daily Dose of Everolimus and Treatment Effect in Patients With Luminal HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2023;43:5253-5259.
    PubMed     Abstract available

    October 2023
  5. JUNKINS K, Rodgers M, Phelan SA
    Oleuropein Induces Cytotoxicity and Peroxiredoxin Over-expression in MCF-7 Human Breast Cancer Cells.
    Anticancer Res. 2023;43:4333-4339.
    PubMed     Abstract available

  6. PETRELLI F, Rea C, Parati MC, Borgonovo K, et al
    Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2023;43:4303-4313.
    PubMed     Abstract available

  7. CIPOLLA C, Vieni S, D'Agati E, Grassi N, et al
    Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2023;43:4643-4649.
    PubMed     Abstract available

  8. EGGERT MC, Janssen S, Yu NY, Rades D, et al
    Simultaneous vs. Sequential Boost for Adjuvant Breast Radiotherapy.
    Anticancer Res. 2023;43:4651-4655.
    PubMed     Abstract available

  9. JANG SH, Paek SH, Kim JK, Seong JK, et al
    Estrogen Effects Differ Between Medium Maintenance and Replacement from Transcriptional and Clinical Perspectives in T47D Breast Cancer Cells.
    Anticancer Res. 2023;43:4447-4469.
    PubMed     Abstract available

    September 2023
  10. ZHUANG X, Ji W, Fang Z, Yang Y, et al
    Claudin-10 in the Blood Brain Barrier Function of Cerebral Endothelial Cells and Transendothelial Invasion of Breast Cancer Cells.
    Anticancer Res. 2023;43:3923-3934.
    PubMed     Abstract available

  11. GODA N, Funakoshi M, Ono C, Mukaida H, et al
    Dual-energy Computed Tomography Iodine Map for Breast Cancer: Comparison With Dynamic Contrast-enhanced Magnetic Resonance Imaging.
    Anticancer Res. 2023;43:4133-4142.
    PubMed     Abstract available

  12. HIGASHI C, Saito K, Kozuka Y, Yuasa H, et al
    Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer.
    Anticancer Res. 2023;43:4045-4053.
    PubMed     Abstract available

  13. MCLAUGHLIN AJ, Kaniski AJ, Matti DI, Xhabija B, et al
    Comparative Morphological Analysis of MCF10A and MCF7 Cells Using Holographic Time-lapse Microscopy.
    Anticancer Res. 2023;43:3891-3896.
    PubMed     Abstract available

  14. ZABROCKA E, Newman B, Levey G, Sweeney K, et al
    Estrogen Receptor-negative Ductal Carcinoma In Situ (DCIS) of the Breast - an Institutional Review of Outcomes.
    Anticancer Res. 2023;43:4031-4036.
    PubMed     Abstract available

    August 2023
  15. LEE YC, Tang CT, Kan JY, Chiang CP, et al
    Correlation of Beta2-Glycoprotein I With Tumor Prognosis in Breast Cancer Patients.
    Anticancer Res. 2023;43:3455-3462.
    PubMed     Abstract available

  16. JINGU K, Umezawa R, Yamamoto T, Takahashi N, et al
    Recent Postoperative Radiotherapy for Left-sided Breast Cancer Does Not Increase Mortality of Heart Disease in Asians or Pacific Islanders: SEER Database Analysis.
    Anticancer Res. 2023;43:3571-3577.
    PubMed     Abstract available

  17. NAMIKAWA T, Yokota K, Maeda H, Kitagawa H, et al
    Gastric and Bone Metastases Arising from Invasive Lobular Carcinoma With Ductal Carcinoma Occurring in one Breast Synchronously.
    Anticancer Res. 2023;43:3701-3707.
    PubMed     Abstract available

    July 2023
  18. CHEN SK, Lee W, Li YC, Hsu FT, et al
    Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.
    Anticancer Res. 2023;43:2985-2994.
    PubMed     Abstract available

  19. CHOI EY, Jung GH, Woo JS, Lee JH, et al
    Dendropanax morbiferus H. Lev. Leaf Extract Inhibits the Proliferation of MDA-MB-231 Breast Cancer Cells and Induces Apoptosis via the MAPK Pathway In Vitro and In Vivo.
    Anticancer Res. 2023;43:3047-3056.
    PubMed     Abstract available

  20. HAN YH, Wang Y, Lee SJ, Mao YY, et al
    Identification of Hub Genes and Upstream Regulatory Factors Based on Cell Adhesion in Triple-negative Breast Cancer by Integrated Bioinformatical Analysis.
    Anticancer Res. 2023;43:2951-2964.
    PubMed     Abstract available

  21. SEO Y, Lee J, Kim J, Shim S, et al
    FOXJ3 Regulates Cell Proliferation and Motility Through Modulating Snail Expression in Breast Cancer Cells.
    Anticancer Res. 2023;43:2995-3001.
    PubMed     Abstract available

  22. VANNI G, Materazzo M, Pellicciaro M, Caspi J, et al
    Anxiety and Fear of Breast Cancer Patients During and After the COVID-19 Era.
    Anticancer Res. 2023;43:3255-3263.
    PubMed     Abstract available

    June 2023
  23. BUENTZEL J, Schulz M, Aperdannier L, Bleckmann A, et al
    Metabolic Changes in Blood-derived Extracellular Vesicles of Malnourished Breast Cancer Patients.
    Anticancer Res. 2023;43:2593-2599.
    PubMed     Abstract available

  24. FENG K, Jian C, Xiao H, Jiang H, et al
    The Suppressive Effect of Rebastinib on Triple-negative Breast Cancer Tumors Involves Multiple Mechanisms of Action.
    Anticancer Res. 2023;43:2609-2624.
    PubMed     Abstract available

  25. KANGA KJW, Kanga LHB, Mendonca P, Soliman KFA, et al
    Attenuative Effect of Diallyl Trisulfide on Caspase Activity in TNF-alpha-induced Triple Negative Breast Cancer Cells.
    Anticancer Res. 2023;43:2393-2405.
    PubMed     Abstract available

  26. CHAWLA SP, Olevsky O, Iyengar G, Brigham DA, et al
    Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor.
    Anticancer Res. 2023;43:2383-2391.
    PubMed     Abstract available

  27. MORITA M, Ooe A, Ishii W, Watanabe A, et al
    Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib.
    Anticancer Res. 2023;43:2783-2789.
    PubMed     Abstract available

  28. OLIVA D, Andersson BA, Shamoun L, Lewin N, et al
    Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39).
    Anticancer Res. 2023;43:2671-2681.
    PubMed     Abstract available

    May 2023
  29. CHU J, Kim HS, DO SI
    Clinicopathological Significance and Predictive Value of High Intratumoral Tumor Budding in Patients With Breast Carcinoma Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2023;43:2323-2332.
    PubMed     Abstract available

  30. MIYASAKA Y, Yoshimoto Y, Ando K, Murata K, et al
    CD8-positive Tumor-infiltrating Lymphocytes and Prognosis in Radiotherapy for Uterine Cervical Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:2077-2084.
    PubMed     Abstract available

  31. OMORI S, Shigechi T, Kawaguchi K, Ijichi H, et al
    Successful Prevention of Tumour Lysis Syndrome in HER2-positive Breast Cancer: Case Report and Literature Review.
    Anticancer Res. 2023;43:2371-2377.
    PubMed     Abstract available

  32. ZWICKER F, Klepper R, Hauswald H, Hoefel S, et al
    Helical Tomotherapy of Lymph Node-negative Early-stage Breast Cancer After Breast-conserving Surgery: Long-term Results.
    Anticancer Res. 2023;43:2041-2053.
    PubMed     Abstract available

  33. GOSSET M, Gal J, Schiappa R, Helwig C, et al
    Breast Cancer and SARS-Cov2: Lessons from a Pandemic.
    Anticancer Res. 2023;43:2235-2241.
    PubMed     Abstract available

  34. YAMANAKA T, Oshima T, Murayama D, Okamoto S, et al
    Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer.
    Anticancer Res. 2023;43:2145-2154.
    PubMed     Abstract available

  35. MEUCCI R, Buonomo OC, Perretta T, Manenti G, et al
    Vacuum-assisted Evacuation (VAEv) of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries and Percutaneous Procedures.
    Anticancer Res. 2023;43:2135-2143.
    PubMed     Abstract available

  36. KIM EY, Ahn S
    Epithelial-mesenchymal Transition Factor and Its Association With Mammographic Density and Breast Cancer Prognosis.
    Anticancer Res. 2023;43:2281-2292.
    PubMed     Abstract available

  37. KIM YJ, Jang SK, Kim G, Hong SE, et al
    Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors.
    Anticancer Res. 2023;43:1973-1980.
    PubMed     Abstract available

  38. PARK NR, Lee YJ, Lee SH, Kim JE, et al
    Anti-cancer Effect of Unique Cartilage Matrix-associated Protein in Breast Cancer Cells Depends on gamma-Carboxylation.
    Anticancer Res. 2023;43:1959-1965.
    PubMed     Abstract available

  39. SUSINI T, Nesi I, Renda I, Giani M, et al
    Reducing the Use of Frozen Section for Sentinel Node Biopsy in Breast Carcinoma: Feasibility and Outcome.
    Anticancer Res. 2023;43:2161-2170.
    PubMed     Abstract available

    April 2023
  40. ONISHI M, Yamaguchi S, Wen X, Han M, et al
    TP53 Signature Score Predicts Prognosis and Immune Response in Triple-negative Breast Cancer.
    Anticancer Res. 2023;43:1731-1739.
    PubMed     Abstract available

  41. BUONOMO OC, Pellicciaro M, Materazzo M, Berardi S, et al
    Surgical Treatments for Ductal Carcinoma In Situ (DCIS) in Elderly Patients.
    Anticancer Res. 2023;43:1555-1562.
    PubMed     Abstract available

  42. STEFANOVIC S, Wirtz R, Sutterlin M, Karic U, et al
    Cut-off Analysis of HLA-A and HLA-B/C Expression as a Potential Prognosticator of Favorable Survival in Patients With Metastatic Breast Cancer.
    Anticancer Res. 2023;43:1449-1454.
    PubMed     Abstract available

    March 2023
  43. SEMKOVA S, Nikolova B, Tsoneva I, Antov G, et al
    Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells.
    Anticancer Res. 2023;43:1207-1212.
    PubMed     Abstract available

  44. COLLERY P, Michalke B, Lucio M, Varlet D, et al
    Plasma Rhenium and Selenium Concentrations After Repeated Daily Oral Administration of Rhenium(I)-diselenoether in 4T1 Breast Tumor-bearing Mice.
    Anticancer Res. 2023;43:1017-1023.
    PubMed     Abstract available

  45. YOU D, Kim H, Jeong Y, Yoon SY, et al
    Chemokine (C-C motif) Ligand 2 Is Regulated Through the EGFR/Src Pathway in HER2-positive Breast Cancer Cells.
    Anticancer Res. 2023;43:1079-1089.
    PubMed     Abstract available

  46. NADAI T, Narumi K, Mukai Y, Ueda H, et al
    5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells.
    Anticancer Res. 2023;43:1113-1120.
    PubMed     Abstract available

  47. MAEDA A, Ando H, Irie K, Hashimoto N, et al
    Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18).
    Anticancer Res. 2023;43:1283-1289.
    PubMed     Abstract available

  48. KO YC, Choi HS, Kim SL, Lee DS, et al
    Isophysalin A Inhibits the Stemness of Breast Cancer Cells Possibly via Stat3 and IL-6 Signaling.
    Anticancer Res. 2023;43:1091-1101.
    PubMed     Abstract available

  49. VOUTSADAKIS IA, Stravodimou A
    Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.
    Anticancer Res. 2023;43:967-981.
    PubMed     Abstract available

  50. GEBBIA V, Martorana F, Sano MV, Valerio MR, et al
    Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data.
    Anticancer Res. 2023;43:1291-1299.
    PubMed     Abstract available

  51. IKEDA M, Kataoka Y, Taji T, Suwa H, et al
    Half Dose Pegfilgrastim for Patients With Breast Cancer During Chemotherapy: A Case-series.
    Anticancer Res. 2023;43:1373-1375.
    PubMed     Abstract available

  52. BIMONTE S, Palma G, Cascella M, Cuomo A, et al
    Phytocannabinoids in Triple Negative Breast Cancer Treatment: Current Knowledge and Future Insights.
    Anticancer Res. 2023;43:993-1000.
    PubMed     Abstract available

    February 2023
  53. TAKADA K, Kashiwagi S, Iimori N, Kouhashi R, et al
    Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer.
    Anticancer Res. 2023;43:849-856.
    PubMed     Abstract available

  54. SCALIA G, Costanzo R, Viola A, Bonosi L, et al
    Intramedullary Spinal Cord Metastases from Breast Cancer: A Systematic Review.
    Anticancer Res. 2023;43:523-535.
    PubMed     Abstract available

  55. GOTO W, Kashiwagi S, Iimori N, Kouhashi R, et al
    Eribulin Treatment Promotes Re-expression of Estrogen Receptor in Endocrine Therapy-resistant Hormone Receptor-positive Breast Cancer Cells.
    Anticancer Res. 2023;43:603-611.
    PubMed     Abstract available

  56. BUONOMO OC, Materazzo M, Pellicciaro M, Iafrate G, et al
    Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride for Identification of Sentinel Lymph Nodes During Breast Cancer Surgery: A Clinical Trial.
    Anticancer Res. 2023;43:557-567.
    PubMed     Abstract available

  57. YAMASHITA H, Hatanaka KC, Yamagishi K, Saito Y, et al
    Evaluation of 95-Gene Classifier of Formalin-fixed Paraffin-embedded Tissues in ER-positive, HER2-negative, and Node-negative Breast Cancer.
    Anticancer Res. 2023;43:707-711.
    PubMed     Abstract available

  58. KOLBERG HC, Niesing H, Vaidya JS, Akpolat-Basci L, et al
    Breast Conserving Surgery in Combination With Targeted Intraoperative Radiotherapy Compared to Mastectomy for In-breast-tumor-recurrence.
    Anticancer Res. 2023;43:733-739.
    PubMed     Abstract available

    January 2023
  59. KIMURA Y, Sasada S, Emi A, Masumoto N, et al
    (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer.
    Anticancer Res. 2023;43:127-136.
    PubMed     Abstract available

  60. GOTO W, Kashiwagi S, Matsuoka K, Iimori N, et al
    Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2023;43:247-254.
    PubMed     Abstract available

  61. KATUWAL NB, Park N, Pandey K, Kang MS, et al
    Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.
    Anticancer Res. 2023;43:85-95.
    PubMed     Abstract available

  62. LEE JH
    Phosphofructokinase 1 Platelet Isoform Enhances VEGF Expression in Part Through HIF-1alpha Up-regulation in Breast Cancer.
    Anticancer Res. 2023;43:75-84.
    PubMed     Abstract available

  63. MIMOUN C, Legay L, Lorphelin H, Leveau-Vallier AS, et al
    Histological Risk Factors for Local Recurrence of Phyllodes Tumors of the Breast.
    Anticancer Res. 2023;43:143-147.
    PubMed     Abstract available

  64. KIKUCHI M, Fujii T, Honda C, Tanabe K, et al
    Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years.
    Anticancer Res. 2023;43:217-221.
    PubMed     Abstract available

  65. COLBOURNE JRM, Toniolo JT, Diacon A, Lawrentschuk N, et al
    Following the Trend: A Comparative Analysis of Public Engagement and Funding for Annual Prostate and Breast Cancer Campaigns Using Google Trends.
    Anticancer Res. 2023;43:409-415.
    PubMed     Abstract available

  66. TAKADA K, Kashiwagi S, Iimori N, Kouhashi R, et al
    Factor Analysis of Intraoperative Bleeding Loss and its Impact on Prognosis in Breast Cancer.
    Anticancer Res. 2023;43:191-200.
    PubMed     Abstract available

    December 2022
  67. SUKNIAM K, Kasbi AA, Ali M, Popp K, et al
    Disparities in Time to Treatment for Breast Cancer.
    Anticancer Res. 2022;42:5813-5818.
    PubMed     Abstract available

  68. SUZUKI K, Sasada S, Kimura Y, Emi A, et al
    Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
    Anticancer Res. 2022;42:5945-5949.
    PubMed     Abstract available

  69. APESSOS A, Agiannitopoulos K, Pepe G, Tsaousis GN, et al
    Genetic Predisposition to Male Breast Cancer: A Case Series.
    Anticancer Res. 2022;42:5795-5801.
    PubMed     Abstract available

  70. TANIGUCHI A, Kittaka N, Kanaoka H, Nakajima S, et al
    Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis.
    Anticancer Res. 2022;42:6027-6035.
    PubMed     Abstract available

  71. KUBOTA Y, Han Q, Masaki N, Hozumi C, et al
    Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
    Anticancer Res. 2022;42:5819-5823.
    PubMed     Abstract available

    November 2022
  72. MIZRAHI AG, Hamad H, Gugenheim A, Nisman B, et al
    Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
    Anticancer Res. 2022;42:5257-5263.
    PubMed     Abstract available

  73. TAKAHASHI E, Imai K, Fukuyama M, Terata K, et al
    Changes in Serum Trace Element Concentrations Before and After Surgery in Resectable Breast Cancer.
    Anticancer Res. 2022;42:5323-5334.
    PubMed     Abstract available

  74. XIONG Y, Motomura H, Tamori S, Ozaki A, et al
    High Expression of CD58 and ALDH1A3 Predicts a Poor Prognosis in Basal-like Breast Cancer.
    Anticancer Res. 2022;42:5223-5232.
    PubMed     Abstract available

  75. SCHMITZ V, Bauerschmitz G, Gallwas J, Grundker C, et al
    Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERbeta Agonists.
    Anticancer Res. 2022;42:5187-5194.
    PubMed     Abstract available

  76. SHOJI R, Tsuchie H, Nagasawa H, Hongo M, et al
    Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
    Anticancer Res. 2022;42:5357-5363.
    PubMed     Abstract available

    October 2022
  77. KANAOKA H, Nagahashi M, Atake Y, Hattori A, et al
    Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Anticancer Res. 2022;42:4867-4878.
    PubMed     Abstract available

  78. OZAWA H, Higuchi T, Fujimoto Y, Bun A, et al
    Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.
    Anticancer Res. 2022;42:4813-4824.
    PubMed     Abstract available

  79. MORI T, Furukawa A, Bilal T, Ueda A, et al
    Simultaneous Detection and HER2 Profiling of Circulating Breast Cancer Cells in Clinical Patients Using a Rare Cell Sorter.
    Anticancer Res. 2022;42:4879-4886.
    PubMed     Abstract available

  80. MUGURUMA M, Asaoka M, Teraoka S, Miyahara K, et al
    beta-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines.
    Anticancer Res. 2022;42:4735-4742.
    PubMed     Abstract available

    September 2022
  81. DO J, Chu J, Ahn J, Bae GE, et al
    Assessing Resection Margin Status in Breast-conserving Surgery Specimens: Comparison Among Gross Evaluation, Frozen Section Analysis, and Permanent Section Diagnosis in 725 Patients With Breast Cancer.
    Anticancer Res. 2022;42:4453-4460.
    PubMed     Abstract available

  82. II H, Taniguchi K, Yoshiya T, Nohara Y, et al
    The gamma-Glutamylcyclotransferase Inhibitor Pro-GA Induces an Antiproliferative Effect Through the Generation of Mitochondrial Reactive Oxygen Species.
    Anticancer Res. 2022;42:4311-4317.
    PubMed     Abstract available

  83. SON SW, Heo SH, Oh SS, Lee CH, et al
    Etoposide-induced MicroRNA-205-5p Suppresses Proliferation and Migration by Targeting ERBB4 in MCF-7 Cells.
    Anticancer Res. 2022;42:4265-4272.
    PubMed     Abstract available

    August 2022
  84. TAKADA K, Kashiwagi S, Kouhashi R, Iimori N, et al
    The Effect of Smoking on Endocrine Therapy for Stage IV Hormone Receptor Positive Breast Cancer.
    Anticancer Res. 2022;42:3937-3946.
    PubMed     Abstract available

  85. SHIMAZAKI A, Kubo M, Kurata K, Takao Y, et al
    CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients.
    Anticancer Res. 2022;42:4071-4077.
    PubMed     Abstract available

  86. LIAO PA, Chu PY, Tan ZL, Hsu FT, et al
    STAT3 Inactivation and Induction of Apoptosis Associate With Fluoxetine-inhibited Epithelial-mesenchymal Transition and Growth of Triple-negative Breast Cancer In Vivo.
    Anticancer Res. 2022;42:3807-3814.
    PubMed     Abstract available

  87. OGATA N, Toh U, Sudou T, Ogata S, et al
    Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
    Anticancer Res. 2022;42:4139-4143.
    PubMed     Abstract available

  88. KITANO S, Honda A, Itoi N, Lee T, et al
    Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors.
    Anticancer Res. 2022;42:3913-3919.
    PubMed     Abstract available

  89. WANG YC, Wang ZH, Yen JH, Shen YC, et al
    The Contribution of Interleukin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Risk in Taiwan.
    Anticancer Res. 2022;42:3799-3806.
    PubMed     Abstract available

  90. VANNI G, Pellicciaro M, Materazzo M, Melaiu O, et al
    Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study.
    Anticancer Res. 2022;42:3879-3888.
    PubMed     Abstract available

  91. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors.
    Anticancer Res. 2022;42:4179-4187.
    PubMed     Abstract available

    July 2022
  92. NOZAWA K, Takatsuka D, Endo Y, Horisawa N, et al
    Impact of Tumor Progression on Survival During Neoadjuvant Chemotherapy in Breast Cancer: A Cohort Study.
    Anticancer Res. 2022;42:3735-3742.
    PubMed     Abstract available

  93. OZAKI A, Motomura H, Tamori S, Onaga C, et al
    High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
    Anticancer Res. 2022;42:3299-3312.
    PubMed     Abstract available

  94. SAITO Y, Takekuma Y, Takeshita T, Noguchi T, et al
    Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment.
    Anticancer Res. 2022;42:3693-3700.
    PubMed     Abstract available

  95. SAITO Y, Takekuma Y, Takeshita T, Sugawara M, et al
    Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens.
    Anticancer Res. 2022;42:3753-3758.
    PubMed     Abstract available

  96. SAEED MEM, Drif AI, Efferth T
    Biomarker Profiling Revealed Carcinoembryonic Antigen as a Target of Artesunate in a Ductal Breast Cancer Patient.
    Anticancer Res. 2022;42:3483-3494.
    PubMed     Abstract available

  97. CHOI HY, Lee HJ, Moon KM, Moon DK, et al
    Up-regulation of CPNE1 Appears to Enhance Cancer Progression in HER2-positive and Luminal A Breast Cancer Cells.
    Anticancer Res. 2022;42:3445-3452.
    PubMed     Abstract available

  98. NIGUMA K, Mamishin K, Naito Y, Nomura S, et al
    Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer.
    Anticancer Res. 2022;42:3743-3751.
    PubMed     Abstract available

    June 2022
  99. RADES D, Narvaez CA, Dziggel L, Splettstosser L, et al
    Improvement of Sleep Disorders During a Course of Radiotherapy for Breast Cancer - Final Results of the Prospective Interventional RADIO-SLEEP Trial.
    Anticancer Res. 2022;42:3085-3089.
    PubMed     Abstract available

  100. ROSENKAIMER S, Sieburg T, Winter L, Mavratzas A, et al
    Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis.
    Anticancer Res. 2022;42:3075-3084.
    PubMed     Abstract available

  101. YEHIA ZA, Yoon J, Sayan M, Kumar S, et al
    Does the Use of BioZorb((R)) Result in Smaller Breast Seroma Volume?
    Anticancer Res. 2022;42:2961-2965.
    PubMed     Abstract available

    May 2022
  102. CHUNG Y, Kim S, Kim HS, DO SI, et al
    High Receptor-interacting Serine/Threonine-protein Kinase 3 (RIP3) Expression Serves as an Independent Poor Prognostic Factor for Triple-negative Breast Carcinoma.
    Anticancer Res. 2022;42:2753-2761.
    PubMed     Abstract available

  103. HAN M, Yamaguchi S, Onishi M, Fujii T, et al
    The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer.
    Anticancer Res. 2022;42:2277-2288.
    PubMed     Abstract available

  104. TAKEMURA M, Ikemura K, Yoshinami T, Toyozumi Y, et al
    Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.
    Anticancer Res. 2022;42:2591-2598.
    PubMed     Abstract available

  105. TUOHINEN SS, Skytta T, Huhtala H, Virtanen V, et al
    Dynamic Integrated Backscatter Detects Radiotherapy-induced Cardiac Changes Better than Strain Analysis - A Prospective Three-year Study.
    Anticancer Res. 2022;42:2507-2517.
    PubMed     Abstract available

  106. NISHIMURA M, Imaoka T, Daino K, Nishimura Y, et al
    Copenhagen Rats Display Dominantly Inherited Yet Non-uniform Resistance to Spontaneous, Radiation-induced, and Chemically-induced Mammary Carcinogenesis.
    Anticancer Res. 2022;42:2415-2423.
    PubMed     Abstract available

    April 2022
  107. TANAKA M, Yamashita SI, Yoshinaga Y, Enomoto Y, et al
    Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence.
    Anticancer Res. 2022;42:2079-2085.
    PubMed     Abstract available

  108. PARK HL, Yang B, Shin JE, Kim JY, et al
    Additional Excision Biopsy in Patients With Atypical Ductal Hyperplasia at Ultrasound-guided Vacuum-assisted Breast Biopsy.
    Anticancer Res. 2022;42:2159-2165.
    PubMed     Abstract available

    March 2022
  109. KASHIWAGI S, Asano Y, Takada K, Goto W, et al
    Outcome Prediction After Neoadjuvant Chemotherapy (NAC) for Breast Cancer, Using Tumor-infiltrating Lymphocytes Within Fibrotic Foci of Tumor Stroma (FF-TILs).
    Anticancer Res. 2022;42:1421-1431.
    PubMed     Abstract available

  110. OKAMOTO A, Funakoshi Y, Oe M, Takai R, et al
    Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1.
    Anticancer Res. 2022;42:1199-1205.
    PubMed     Abstract available

  111. DANTAS FT, Felix-Silva PH, Angotti-Carrara HH, Dos-Reis FJC, et al
    A New Method for Obtaining Tumor Interstitial Fluid Applied to Cytokine Analysis of Breast Carcinoma Samples.
    Anticancer Res. 2022;42:1327-1332.
    PubMed     Abstract available

    February 2022
  112. SEKI H, Sakurai T, Sakurada A, Kinoshita T, et al
    Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2022;42:1099-1106.
    PubMed     Abstract available

  113. ALEXOPOULOS A, Karanikiotis C, Ardavanis A, Boukovinas I, et al
    Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" s
    Anticancer Res. 2022;42:1031-1041.
    PubMed     Abstract available

  114. WAZIR U, Patani N, Heeney J, Mokbel K, et al
    Pre-pectoral Immediate Breast Reconstruction Following Conservative Mastectomy Using Acellular Dermal Matrix and Semi-smooth Implants.
    Anticancer Res. 2022;42:1013-1018.
    PubMed     Abstract available

  115. GOTO W, Kashiwagi S, Takada K, Asano Y, et al
    Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2022;42:939-946.
    PubMed     Abstract available

  116. NIEDER C, Ressheim J, Haukland EC, Mannsaker B, et al
    Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort.
    Anticancer Res. 2022;42:923-928.
    PubMed     Abstract available

  117. COMSA S, Ceausu AR, Popescu R, Cimpean AM, et al
    Patterns of Tumor Vasculogenesis on a Chick Embryo Chorioallantoic Membrane In Vivo Model of Breast Cancer.
    Anticancer Res. 2022;42:877-883.
    PubMed     Abstract available

  118. HO CY, Hu DW, Chen BR, Yang CC, et al
    Snail Mucus Enhances Chemosensitivity of Triple-negative Breast Cancer Via Activation of the Fas Pathway.
    Anticancer Res. 2022;42:845-855.
    PubMed     Abstract available

  119. GOHNO T, Hanamura T, Kurosumi M, Takei H, et al
    One DNA Methylation Regulates CHIP Gene Expression of Human Breast Cancer and Predicts Recurrence.
    Anticancer Res. 2022;42:759-766.
    PubMed     Abstract available

  120. SONG C, Kendi AT, Lowe VJ, Lee S, et al
    The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer.
    Anticancer Res. 2022;42:681-695.
    PubMed     Abstract available

  121. MOKBEL K, Mokbel K
    The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy.
    Anticancer Res. 2022;42:661-666.
    PubMed     Abstract available

    January 2022
  122. MAZAKI AI, Yamauchi K, Orita S, Inage K, et al
    Nerve Growth Factor in Breast Cancer Cells Promotes Axonal Growth and Expression of Calcitonin Gene-related Peptide in a Rat Model of Spinal Metastasis.
    Anticancer Res. 2022;42:581-587.
    PubMed     Abstract available

    Cholesterol Depletion Modulates Drug Resistance Pathways to Sensitize Resistant Breast Cancer Cells to Tamoxifen.
    Anticancer Res. 2022;42:565-579.
    PubMed     Abstract available

  124. HOSOYA K, Nosaka K, Sakabe T, Wakahara M, et al
    Clinical Significance of Serglycin Expression in Human Breast Cancer Patients.
    Anticancer Res. 2022;42:279-285.
    PubMed     Abstract available

  125. MEIROVITZ A, Nisman B, Allweis TM, Carmon E, et al
    Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer Res. 2022;42:253-261.
    PubMed     Abstract available

  126. ASANO Y, Kashiwagi S, Takada K, Ishihara S, et al
    Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
    Anticancer Res. 2022;42:125-136.
    PubMed     Abstract available

  127. SAYAN M, Vergalasova I, Jan I, Kumar S, et al
    Toxicities and Locoregional Control After External Beam Chest Wall and/or Regional Lymph Node Re-irradiation for Recurrent Breast Cancer.
    Anticancer Res. 2022;42:93-96.
    PubMed     Abstract available

  128. SAYAN M, Yehia ZA, Jan I, Gupta A, et al
    Adaptive Lumpectomy Boost Planning Can Reduce Normal Tissue Exposure in Patients Receiving Hypofractionated Whole Breast Irradiation.
    Anticancer Res. 2022;42:53-57.
    PubMed     Abstract available

  129. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study.
    Anticancer Res. 2022;42:311-320.
    PubMed     Abstract available

    December 2021
  130. MAMISHIN K, Naito Y, Nomura S, Ogawa G, et al
    Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2021;41:6217-6224.
    PubMed     Abstract available

  131. HONG SE, Jin HO, Kim SM, Jang SK, et al
    miR-3188 Enhances Sensitivity of Breast Cancer Cells to Ionizing Radiation by Down-regulating Rictor.
    Anticancer Res. 2021;41:6169-6176.
    PubMed     Abstract available

  132. MOTOMURA H, Tamori S, Yatani MA, Namiki A, et al
    GLO 1 and PKClambda Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
    Anticancer Res. 2021;41:5959-5971.
    PubMed     Abstract available

  133. ACUNA UM, Ezzone N, Rakotondraibe LH, Carcache DE Blanco EJ, et al
    Activity in MCF-7 Estrogen-sensitive Breast Cancer Cells of Capsicodendrin from Cinnamosma fragrans.
    Anticancer Res. 2021;41:5935-5944.
    PubMed     Abstract available

  134. KANGA KJW, Mendonca P, Soliman KFA, Ferguson DT, et al
    Effect of Diallyl Trisulfide on TNF-alpha-induced CCL2/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2021;41:5919-5933.
    PubMed     Abstract available

  135. NOMURA T, Kurebayashi J, Moriya T, Saito W, et al
    A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
    Anticancer Res. 2021;41:6191-6197.
    PubMed     Abstract available

  136. COLLERY P, Veena V, Desmaele D, Harikrishnan A, et al
    Effects of Rhenium(I)-diselenoether and of its Diselenide Ligand on the Production of Cathepsins B and S by MDA-MB231 Breast Malignant Cells.
    Anticancer Res. 2021;41:5997-6001.
    PubMed     Abstract available

    November 2021
  137. TOKISAWA H, Aruga T, Honda Y, Ishiba T, et al
    Safety and Effectiveness of Areola-sparing Mastectomy for Breast Cancer With Intraductal Lesions.
    Anticancer Res. 2021;41:5723-5728.
    PubMed     Abstract available

  138. PIANKA J, Gruba N, Kitowska K, Mieczkowski K, et al
    Simplified Theta-defensin [Ser(3,7,12,16)] RTD-2 Analog Is Involved in Proteasomal Degradation Pathway in Breast Cancer.
    Anticancer Res. 2021;41:5415-5423.
    PubMed     Abstract available

  139. VANNI G, Caiazza G, Materazzo M, Storti G, et al
    Erector Spinae Plane Block Versus Serratus Plane Block in Breast Conserving Surgery: Alpha Randomized Controlled Trial.
    Anticancer Res. 2021;41:5667-5676.
    PubMed     Abstract available

  140. VANNI G, Pellicciaro M, Sadri A, Tacconi F, et al
    Pre-pectoral Breast Reconstruction Does Not Affect Early Immunological Response: A BIAL 2.20 Study Subanalysis.
    Anticancer Res. 2021;41:5657-5665.
    PubMed     Abstract available

    October 2021
  141. FRIEDRICH RE, Madani E
    Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer.
    Anticancer Res. 2021;41:5081-5087.
    PubMed     Abstract available

  142. VAHAAHO N, Hakamies-Blomqvist L, Blomqvist C, Kellokumpu-Lehtinen PL, et al
    Sense of Coherence as Predictor of Quality of Life in Early Breast Cancer Patients.
    Anticancer Res. 2021;41:5045-5052.
    PubMed     Abstract available

  143. TAKASHIMA T, Nishimura S, Kawajiri H, Mizuyama Y, et al
    An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
    Anticancer Res. 2021;41:5007-5014.
    PubMed     Abstract available

  144. WU NF, Yamamoto J, Aoki Y, Masaki N, et al
    The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
    Anticancer Res. 2021;41:4715-4718.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.